Pathologic Staging (pTNM)
CAP Approved Genitourinary • Urethra 4.0.0.0 (AJCC 8th ed.)
TNM Descriptors (required only if applicable) (select all that apply)
___ m (multiple primary tumors)
___ r (recurrent)
___ y (posttreatment)
Primary Tumor (pT) For male penile urethra and female urethra
___ pTX: |
Cannot be assessed |
___ pT0: |
No evidence of primary tumor |
___ pTa: |
Noninvasive papillary carcinoma |
___ pTis: |
Carcinoma in situ |
___ pT1: |
Tumor invades subepithelial connective tissue |
___ pT2: |
Tumor invades any of the following: corpus spongiosum, periurethral muscle |
___ pT3: |
Tumor invades any of the following: corpus cavernosum, beyond prostatic capsule, anterior vagina, bladder neck |
___ pT4: |
Tumor invades other adjacent organs (eg, invasion of the bladder wall) |
Primary Tumor (pT) For urothelial carcinoma of the prostatic urethra
___ pTX: Cannot be assessed
___ pT0: No evidence of primary tumor
___ pTa: Noninvasive papillary carcinoma
___ pTis pu: Carcinoma in situ, involvement of prostatic urethra
___ pTis pd: Carcinoma in situ, involvement of prostatic ducts
___ pT1: |
Tumor invades subepithelial connective tissue (only applied to tumors invading from the urethral lumen)# |
___ pT2: |
Tumor invades any of the following: prostatic stroma, corpus spongiosum, periurethral muscle |
___ pT3: |
Tumor invades any of the following: corpus cavernosum, beyond prostatic capsule, bladder neck (extraprostatic extension) |
___ pT4: |
Tumor invades other adjacent organs (invasion of the bladder) |
# Tumors invading directly from prostatic ducts colonized by carcinoma in-situ are designated as at least pT2, regardless of depth or extent of invasion (i.e., there is no pT1 category in that setting).
Regional Lymph Nodes (pN)
___ pNX: Cannot be assessed
___ pN0: No regional lymph node metastasis
___ pN1: Metastasis in a single lymph node 2 cm or less in greatest dimension
___ pN2: Metastasis in a single lymph node more than 2 cm in greatest dimension, or in multiple nodes
Distant Metastasis (pM)
___ Not applicable
___ pM1: Distant metastasis (specify site(s) if known)
Urethra CAP 4.0.0.0 summary of pTNM changes AJCC 7th to 8th edition